VBI Vaccines Inc Uncategorized Contracts & Agreements
27 Contracts & Agreements
- Extension Agreement, dated November 3, 2023, by and among VBI Vaccines Inc., Variation Biotechnologies Inc. and K2 HealthVentures LLC (Filed With SEC on November 14, 2023)
- Extension Agreement, dated October 27, 2023, by and among VBI Vaccines Inc., Variation Biotechnologies Inc. and K2 HealthVentures LLC (Filed With SEC on November 14, 2023)
- Letter Agreement, dated July 5, 2023, by and between VBI Vaccines Inc. and Brii Biosciences (Filed With SEC on November 14, 2023)
- Eighth Amendment to the Collaborative Research Agreement, signed April 17, 2023, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on May 15, 2023)
- Seventh Amendment to the Collaborative Research Agreement, signed February 28, 2023, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on March 13, 2023)
- Open Market Sale AgreementSM, dated August 26, 2022, by and between VBI Vaccines, Inc. and Jefferies LLC (Filed With SEC on November 10, 2022)
- Sixth Amendment to the Collaborative Research Agreement, signed April 28, 2022, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on May 9, 2022)
- Fifth Amendment Five to the Collaborative Research Agreement, signed February 8, 2022, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on March 7, 2022)
- Fourth Amendment to the Collaborative Research Agreement, signed November 15, 2021, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on March 7, 2022)
- Third Amendment to the Collaborative Research Agreement, dated August 27, 2021, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on March 7, 2022)
- Second Amendment to the Collaborative Research Agreement, dated July 8, 2021, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on March 7, 2022)
- First Amendment to the Collaborative Research Agreement, dated December 21, 2020, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on March 7, 2022)
- Collaborative Research Agreement, dated March 30, 2020, between National Research Council of Canada and Variation Biotechnologies Inc (Filed With SEC on March 7, 2022)
- Amendment to the Agreement signed by NRC on March 30, 2020 and Amendment One signed by NRC on December 31, 2020 and Amendment Two signed July 8, 2021 effective August 27, 2021 (Filed With SEC on November 8, 2021)
- Open Market Sale Agreement, dated September 3, 2021, by and between VBI Vaccines Inc. and Jefferies LLC (Filed With SEC on September 3, 2021)
- Amendment to the Agreement signed by NRC on March 30, 2020 and Amendment One signed by NRC on December 21, 2020 effective July 8, 2021 (Filed With SEC on August 2, 2021)
- Amendment One to Collaborative Research Agreement between National Research Council of Canada and Variation Biotechnologies Inc. effective December 21, 2020 (Filed With SEC on March 2, 2021)
- Description of Securities (Filed With SEC on March 2, 2021)
- Collaborative Research Agreement between National Research Council of Canada and Variation Biotechnologies Inc effective March 30, 2020 (Filed With SEC on May 6, 2020)
- Description of Securities (Filed With SEC on March 5, 2020)
- WAIVERAGREEMENT (Filed With SEC on May 15, 2017)
- WAIVERAGREEMENT (Filed With SEC on March 20, 2017)
- INTELLECTUALPROPERTY AND CONFIDENTIAL INFORMATION AGREEMENT (Filed With SEC on March 20, 2017)
- CONSULTINGAGREEMENT (Filed With SEC on March 20, 2017)
- VBIVACCINES INC. INCENTIVESTOCK OPTION AGREEMENT UNDER THEINCENTIVE PLAN (Filed With SEC on March 20, 2017)
- VBIVaccines INC. IncentivePLAN EffectiveMay 6, 2016 Asamended June 23, 2016 (Filed With SEC on March 20, 2017)
- IOGEN CORPORATION, (hereinafter called the Sub-sublandlord), - and - VARIATION BIOTECHNOLOGIES INC., (hereinafter called the Sub-subtenant). (Filed With SEC on March 21, 2016)
